Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 8/2015

01-08-2015 | Meeting Report

Second meeting of the Spanish Immunotherapy Group GEIT (Grupo Español de Inmunoterapia), January 16, 2015, in Zaragoza, Spain

Authors: Alberto Anel, Luis Martínez-Lostao, Julián Pardo

Published in: Cancer Immunology, Immunotherapy | Issue 8/2015

Login to get access

Excerpt

The Spanish Immunotherapy Group (GEIT) is a thematic group created in 2013 inside the Spanish Society for Immunology (SEI), which intends to promote research and dissemination of immunotherapy and to foster collaboration between basic and clinical researchers in this field, currently with 70 members. The second scientific meeting of the GEIT was organized by Alberto Anel and Julián Pardo under the auspices of the Institute of Health Research (IIS) of Aragon and its scientific director Angel Lanas, and moderated by Julián Pardo [Centre for Biomedical Research of Aragon (CIBA), Zaragoza] and Ignacio Melero [Centre for Applied Medical Research (CIMA), Pamplona], and took place on Friday January 16, 2015. The interest in the scientific program of the session was patent, involving 100 researchers, basic and clinical. This meeting was in part intended to foster ties with other scientific societies related to immunotherapy, since the GEIT is intended as a cross-society group, not restricted to members of the Spanish Society of Immunology (SEI). For this reason, and for their scientific reputation, Carlos Martín, member of the Spanish Society for Microbiology, Ana Ortiz, belonging to the Spanish Society for Rheumatology, and Marisol Soengas, member of the Spanish Association of Bio-Enterprises, were invited as speakers. …
Metadata
Title
Second meeting of the Spanish Immunotherapy Group GEIT (Grupo Español de Inmunoterapia), January 16, 2015, in Zaragoza, Spain
Authors
Alberto Anel
Luis Martínez-Lostao
Julián Pardo
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 8/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-015-1732-2

Other articles of this Issue 8/2015

Cancer Immunology, Immunotherapy 8/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine